CN101784544B - 噻二嗪酮衍生物 - Google Patents

噻二嗪酮衍生物 Download PDF

Info

Publication number
CN101784544B
CN101784544B CN2008801040992A CN200880104099A CN101784544B CN 101784544 B CN101784544 B CN 101784544B CN 2008801040992 A CN2008801040992 A CN 2008801040992A CN 200880104099 A CN200880104099 A CN 200880104099A CN 101784544 B CN101784544 B CN 101784544B
Authority
CN
China
Prior art keywords
compounds
formula
salts
pharmaceutically useful
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801040992A
Other languages
English (en)
Chinese (zh)
Other versions
CN101784544A (zh
Inventor
O·沙特
D·多施
F·施蒂贝尔
A·布劳卡特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101784544A publication Critical patent/CN101784544A/zh
Application granted granted Critical
Publication of CN101784544B publication Critical patent/CN101784544B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801040992A 2007-08-30 2008-08-06 噻二嗪酮衍生物 Expired - Fee Related CN101784544B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007041115.6 2007-08-30
DE102007041115A DE102007041115A1 (de) 2007-08-30 2007-08-30 Thiadiazinonderivate
PCT/EP2008/006466 WO2009030333A1 (de) 2007-08-30 2008-08-06 Thiadiazinonderivate

Publications (2)

Publication Number Publication Date
CN101784544A CN101784544A (zh) 2010-07-21
CN101784544B true CN101784544B (zh) 2012-08-29

Family

ID=39952448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801040992A Expired - Fee Related CN101784544B (zh) 2007-08-30 2008-08-06 噻二嗪酮衍生物

Country Status (16)

Country Link
US (1) US8211886B2 (cg-RX-API-DMAC10.html)
EP (1) EP2181111B1 (cg-RX-API-DMAC10.html)
JP (1) JP5524840B2 (cg-RX-API-DMAC10.html)
KR (1) KR20100065171A (cg-RX-API-DMAC10.html)
CN (1) CN101784544B (cg-RX-API-DMAC10.html)
AR (1) AR068130A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008295193B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0816058A2 (cg-RX-API-DMAC10.html)
CA (1) CA2698062C (cg-RX-API-DMAC10.html)
DE (1) DE102007041115A1 (cg-RX-API-DMAC10.html)
EA (1) EA017393B1 (cg-RX-API-DMAC10.html)
ES (1) ES2426356T3 (cg-RX-API-DMAC10.html)
IL (1) IL204127A (cg-RX-API-DMAC10.html)
MX (1) MX2010002096A (cg-RX-API-DMAC10.html)
WO (1) WO2009030333A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201002218B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1101644A (zh) * 1993-04-01 1995-04-19 默克专利股份有限公司 噻二嗪酮

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
BR9813998A (pt) 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
MXPA04003668A (es) 2001-10-31 2004-07-22 Merck Patent Gmbh Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1101644A (zh) * 1993-04-01 1995-04-19 默克专利股份有限公司 噻二嗪酮

Also Published As

Publication number Publication date
KR20100065171A (ko) 2010-06-15
DE102007041115A1 (de) 2009-03-05
JP2010536896A (ja) 2010-12-02
EP2181111B1 (de) 2013-06-26
AU2008295193A1 (en) 2009-03-12
JP5524840B2 (ja) 2014-06-18
US20100311733A1 (en) 2010-12-09
CA2698062C (en) 2016-05-31
MX2010002096A (es) 2010-03-26
BRPI0816058A2 (pt) 2015-03-31
CN101784544A (zh) 2010-07-21
EP2181111A1 (de) 2010-05-05
EA017393B1 (ru) 2012-12-28
IL204127A (en) 2013-08-29
WO2009030333A1 (de) 2009-03-12
ZA201002218B (en) 2010-12-29
HK1146276A1 (en) 2011-05-20
US8211886B2 (en) 2012-07-03
ES2426356T3 (es) 2013-10-22
AU2008295193B2 (en) 2013-04-18
AR068130A1 (es) 2009-11-04
EA201000364A1 (ru) 2010-08-30
CA2698062A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
CN101903374B (zh) 作为met激酶抑制剂的2-苄基哒嗪酮衍生物
JP5426544B2 (ja) ピリミジニル−ピリダジノン誘導体
CN102264727B (zh) 哒嗪酮衍生物
CN101679401B (zh) 用于治疗肿瘤的作为met激酶抑制剂的2-氧代-3-苄基-苯并*唑-2-酮衍生物及相关化合物
JP5576358B2 (ja) ピリダジノン誘導体
CN101678214B (zh) 芳基醚哒嗪酮衍生物
CN102066378B (zh) 作为MET激酶抑制剂的3-(3-嘧啶-2-基苄基)-1，2，4-三唑并[4，3-b]哒嗪衍生物
CN102272125B (zh) 哒嗪酮衍生物
JP2010536719A (ja) ６−チオキソピリダジン誘導体
CN101312958A (zh) 3,6-二氢-2-氧代-6h-1,3,4-噻二嗪衍生物
CN102272112A (zh) 苯并噻唑酮衍生物
JP5576395B2 (ja) ３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ａ］ピリミジン誘導体
JP5524840B2 (ja) チアジアジノン誘導体
CN102264742B (zh) 3-(3-嘧啶-2-基苄基)-1,2,4-三唑并[4,3-b]哒嗪衍生物
HK1146276B (en) Thiadiazinone derivatives
HK1151291B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
HK1164853B (en) Pyridazinone derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146276

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1146276

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120829